MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.26
-0.05
-0.79%
After Hours: 6.20 -0.06 -0.96% 16:43 09/24 EDT
OPEN
6.25
PREV CLOSE
6.31
HIGH
6.49
LOW
6.18
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
18.00
52 WEEK LOW
4.420
MARKET CAP
472.61M
P/E (TTM)
-2.2356
1D
5D
1M
3M
1Y
5Y
Karyopharm Announces Upcoming Virtual Investor Conference Participation
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that , President and Chief Executive Officer, will participate in the following virtual investor confe...
PR Newswire - PRF · 09/07 11:00
Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
and , /PRNewswire/ --
PR Newswire - PRF · 08/24 00:30
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
Zacks.com · 08/20 15:16
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Karyopharm Therapeutics Charts Are Bearish With a Capital B
In this daily bar chart of KPTI, below, we can see that prices have been under selling pressure since February. The On-Balance-Volume (OBV) line is at a new low for the move down, and the Moving Average Convergence Divergence (MACD) oscillator is bearish....
TheStreet.com · 08/13 13:16
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KPTI. Analyze the recent business situations of Karyopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KPTI stock price target is 15.22 with a high estimate of 29.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 230
Institutional Holdings: 69.24M
% Owned: 91.72%
Shares Outstanding: 75.50M
TypeInstitutionsShares
Increased
52
4.27M
New
19
4.60M
Decreased
56
6.42M
Sold Out
37
3.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Director
Richard Paulson
Co-Founder/Director
Michael Kauffman
Chief Financial Officer/Senior Vice President/Treasurer
Michael Mason
Executive Vice President
Ran Frenkel
Executive Vice President
Tanya Lewis
Executive Vice President
Jatin Shah
Senior Vice President/General Counsel/Secretary
Michael Mano
Senior Vice President/Director of Sales
Sohanya Cheng
Senior Vice President/Director of Marketing
Payman Darouian
Senior Vice President
Stephen Mitchener
Chief Scientific Officer
Sharon Shacham
Lead Director/Independent Director
Barry Greene
Independent Director
Garen Bohlin
Independent Director
Mikael Dolsten
Independent Director
Mansoor Mirza
Independent Director
Christy Oliger
Independent Director
Deepa Pakianathan
Independent Director
Chen Schor
No Data
  • All
  • Financials
  • Insiders
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.

Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.